<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04608357</url>
  </required_header>
  <id_info>
    <org_study_id>SUN-2252</org_study_id>
    <nct_id>NCT04608357</nct_id>
  </id_info>
  <brief_title>Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients</brief_title>
  <official_title>Integrated Patient Avatars for Guiding Systemic Therapy Treatments: &quot;Intuition-Free&quot; Decisions in Metastatic Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AFP Innovation Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to use clinically validated patient avatar technology (&quot;PDXovo&quot;)&#xD;
      that can test multiple drugs against patients' cancers to identify the most promising&#xD;
      systemic therapy for each individual.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of this feasibility study is to determine the percentage of patients for&#xD;
      whom PDXs are successfully generated within 7-10 days. This will give the investigators an&#xD;
      indication of the success rate for providing patients with actionable information if this PDX&#xD;
      technology were to be implemented in the clinic. Since the PDXs will also receive the same&#xD;
      drug as the patient, there is an opportunity to assess the agreement between the clinical&#xD;
      response and the PDX response.&#xD;
&#xD;
      As a secondary goal, the response of PDXs will be compared to the patient's response to&#xD;
      systemic therapy, as measured using the objective response rate at 12 weeks +/- 4 weeks (ORR,&#xD;
      measured using RECIST 1.1 criteria).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Determine the tumor take rate in PDX</measure>
    <time_frame>7-10 days</time_frame>
    <description>perform a feasibility study to determine the tumor take rate(s) in PDXs generated from needle core biopsies collected from metastatic breast cancer patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare response rates of PDXs &amp; with that of the patient from whom the PDX was derived</measure>
    <time_frame>8 to 16 weeks</time_frame>
    <description>The response of PDXs will be compared to the patient's response to systemic therapy, as measured using the objective response rate.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Breast Neoplasms</condition>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Cancer, Breast</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Needle Core Biopsies</intervention_name>
    <description>Not an interventional study</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      needle core biopsies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic breast cancer irrespective of subtype prior to receiving either&#xD;
        front-line or subsequent line systemic therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18+.&#xD;
&#xD;
          2. Metastatic breast cancer irrespective of subtype.&#xD;
&#xD;
          3. Measurable disease as per RECIST 1.1 criteria.&#xD;
&#xD;
          4. Metastatic disease involving the lymph nodes and/or visceral organs is required.&#xD;
&#xD;
          5. Willingness to undergo a biopsy prior to the start of planned systemic therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lack of feasibility to obtain a core biopsy of a metastatic site other than the bone&#xD;
             (e.g. a metastatic lesion cannot be safely sampled due to proximity to vasculature).&#xD;
&#xD;
          2. Inability to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katarzyna J Jerzak, MD MSc FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katarzyna J Jerzak, MD MSc FRCPC</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>5248</phone_ext>
    <email>katarzyna.jerzak@sunnybrook.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hon S Leong</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>5748</phone_ext>
    <email>hon.leong@sri.utoronto.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna J Jerzak, MD MSc FRCPC</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>5248</phone_ext>
      <email>katarzyna.jerzak@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Hon S Leong</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>5748</phone_ext>
      <email>hon.leong@sri.utoronto.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Dr. Katarzyna Jerzak</investigator_full_name>
    <investigator_title>Medical Oncologist &amp; Associate Scientist</investigator_title>
  </responsible_party>
  <keyword>metastatic breast cancer</keyword>
  <keyword>systemic therapy</keyword>
  <keyword>needle core biopsy</keyword>
  <keyword>PDXovo</keyword>
  <keyword>feasibility study</keyword>
  <keyword>tumor take rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

